These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29212947)

  • 1. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.
    Pedros C; Canonigo-Balancio AJ; Kong KF; Altman A
    JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
    Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Kinase C-η Deficiency Does Not Impair Antiviral Immunity and CD8
    Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Altman A
    J Immunol; 2020 May; 204(9):2439-2446. PubMed ID: 32198145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
    Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
    J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
    Kumar P; Bhattacharya P; Prabhakar BS
    J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment.
    Gangaplara A; Martens C; Dahlstrom E; Metidji A; Gokhale AS; Glass DD; Lopez-Ocasio M; Baur R; Kanakabandi K; Porcella SF; Shevach EM
    PLoS Pathog; 2018 Apr; 14(4):e1006985. PubMed ID: 29672594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
    Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
    [No Abstract]   [Full Text] [Related]  

  • 11. Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity.
    Nakagawa H; Sido JM; Reyes EE; Kiers V; Cantor H; Kim HJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6248-53. PubMed ID: 27185917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of antigen-expressing dendritic cells by double negative regulatory T cells.
    Gao JF; McIntyre MS; Juvet SC; Diao J; Li X; Vanama RB; Mak TW; Cattral MS; Zhang L
    Eur J Immunol; 2011 Sep; 41(9):2699-708. PubMed ID: 21660936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function.
    Kong KF; Fu G; Zhang Y; Yokosuka T; Casas J; Canonigo-Balancio AJ; Becart S; Kim G; Yates JR; Kronenberg M; Saito T; Gascoigne NR; Altman A
    Nat Immunol; 2014 May; 15(5):465-72. PubMed ID: 24705298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance.
    Hibino S; Chikuma S; Kondo T; Ito M; Nakatsukasa H; Omata-Mise S; Yoshimura A
    Cancer Res; 2018 Jun; 78(11):3027-3040. PubMed ID: 29559474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self.
    Miska J; Bas E; Devarajan P; Chen Z
    Eur J Immunol; 2012 Oct; 42(10):2584-96. PubMed ID: 22777737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
    Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
    Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity.
    Chen X; Du Y; Huang Z
    Immunol Lett; 2012; 148(1):83-9. PubMed ID: 23000301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.
    Bauer CA; Kim EY; Marangoni F; Carrizosa E; Claudio NM; Mempel TR
    J Clin Invest; 2014 Jun; 124(6):2425-40. PubMed ID: 24812664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
    Taylor NA; Vick SC; Iglesia MD; Brickey WJ; Midkiff BR; McKinnon KP; Reisdorf S; Anders CK; Carey LA; Parker JS; Perou CM; Vincent BG; Serody JS
    J Clin Invest; 2017 Sep; 127(9):3472-3483. PubMed ID: 28825599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.